Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001493152-22-028170
Filing Date
2022-10-12
Accepted
2022-10-11 18:36:08
Documents
1
Period of Report
2022-10-11

Document Format Files

Seq Description Document Type Size
1 def14a.htm DEF 14A 509760
  Complete submission text file 0001493152-22-028170.txt   511066
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-12555 | Film No.: 221305051
SIC: 7389 Services-Business Services, NEC